Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
26 mars 2024 08h30 HE
|
Dyadic International, Inc.
The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO. ...
Dyadic to Present at Industry Events in November
30 oct. 2023 08h30 HE
|
Dyadic International, Inc.
Dyadic to Present at Industry Events in November
Dyadic to Participate in Three Upcoming Industry Events
09 juin 2022 09h09 HE
|
Dyadic International, Inc.
JUPITER, Fla., June 09, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...
Dyadic International to Present at Upcoming Scientific Medical Meetings
04 avr. 2022 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., April 04, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and...
Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform
17 déc. 2021 07h00 HE
|
Dyadic International, Inc.
JUPITER, Fla., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Protein Therapeutics Market Worth $ 290, 691.88 Million By 2027, at 6.86% CAGR – Report by Market Research Future (MRFR)
15 juin 2021 13h01 HE
|
Market Research Future
New York, US, June 15, 2021 (GLOBE NEWSWIRE) -- Protein Therapeutics Market Overview: According to a comprehensive research report by Market Research Future (MRFR), “Protein Therapeutics Market -...
Ventria Bioscience aids global fight against intestinal infections that threaten up to 400 million children a year
23 oct. 2017 08h00 HE
|
Ventria Bioscience
JUNCTION CITY, Kan., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Ventria Bioscience Inc. today announced a $4.2 million grant from the Bill & Melinda Gates Foundation to fund development of efficient...